Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.
Nicole Verbeeck is Founder and Editor-in-Chief of Moonshot for Life, covering global health progress. She is also founder of Juneau Cayenne, a creative design, content and technology lab crafting innovative storytelling experiences for clients in healthcare and life sciences worldwide and she is a healthy food chef focusing on prevention of disease.
Become a Moonshot for Life Insider
Join the Moonshot for Life community to access exclusive content, receive email updates, be part of specialized communities, chat with experts, participate in giveaways, and more.
Our Top 3 in Healthcare
Ending Infectious Diseases
6 Health Experts Weighed in on COVID-19 During ‘One World: Together At Home’
Nicole VerbeeckApril 19, 2020